You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)

Not yet recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • JS203 for Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 11, 2022

Non Hodgkin Lymphoma Trial in New York, Clayton, Frankston (IPH6501)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • New York, New York
  • +2 more
Oct 12, 2023

Non-Hodgkin's Lymphoma Trial (MBS303)

Not yet recruiting
  • Non-Hodgkin's Lymphoma
  • (no location specified)
Apr 6, 2023

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Selinexor, Flu, CTX)

Recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 3, 2022

Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,

Recruiting
  • Lymphoma, Non-Hodgkin
  • +6 more
  • CB-010
  • +2 more
  • Scottsdale, Arizona
  • +7 more
Aug 19, 2022

B-cell Non-Hodgkin's Lymphoma Trial in Hangzhou (CD19-CAR-DNT cells)

Recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • CD19-CAR-DNT cells
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 6, 2022

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (RO7443904, Glofitamab, Obinutuzumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • New York, New York
  • +7 more
Jan 11, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

Non-Hodgkin Lymphoma Trial in United States (GDA-201)

Recruiting
  • Non-Hodgkin Lymphoma
  • Maywood, Illinois
  • +4 more
Nov 30, 2022

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Non-hodgkin Lymphoma Trial in United States (MT-3724)

    Terminated
    Has Results
    • Non-hodgkin Lymphoma
    • Whittier, California
    • +4 more
    Jul 18, 2022

    Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Isehara, Chuo-ku (tazemetostat)

    Completed
    Has Results
    • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    • Isehara, Kanagawa, Japan
    • +1 more
    Apr 6, 2022

    NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

    Recruiting
    • NHL
    • NHL, Relapsed, Adult
    • Birmingham, Alabama
    • +4 more
    May 31, 2023

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • (no location specified)
    Aug 7, 2023

    Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igß

    Recruiting
    • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
    • Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Apr 3, 2022

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

    Enrolling by invitation
    • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Mar 22, 2023

    B-Cell Non-Hodgkin's Lymphoma Trial in China (HMPL-760)

    Not yet recruiting
    • B-Cell Non-Hodgkin's Lymphoma
    • Zhengzhou, Henan, China
    • +4 more
    Dec 28, 2021

    Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

    Suspended
    • Recurrent Aggressive Non-Hodgkin Lymphoma
    • +5 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 12, 2023